Key facts
- Navigantis’s last known valuation is $32.9M.
- It has raised $12.8M across 2 recorded rounds; the latest was Early Stage VC ($9.1M) in Apr 2024.
- Notable investors include Mirae Asset Capital, Cormorant Asset Management, Florida Opportunity Fund, Puma Venture Capital.
- Navigantis has filed 2 Form Ds with the SEC since 2023, most recently May 2024 ($9.1M sold to 23 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Navigantis
Create free account
No card required
Funding rounds
2 roundsAbout Navigantis
Developer of neurovascular care designed to empower physicians to deliver uncompromised neurovascular care. The company is currently operating in Stealth Mode.
- Sector
- Healthcare
- HQ
- Miami, FL, United States
- Founded
- 2022
- Employees
- 16
- Website
- navigantis.co/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Navigantis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Navigantis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Navigantis in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.